The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Emerging therapeutic strategies and clinical trials in ATTR-CM
Ronald Witteles, MD, Stanford University, Stanford, CA, discusses the evolving treatment landscape for transthyretin amyloid cardiomyopathy (ATTR-CM). Dr Witteles highlights investigational approaches including TTR-lowering agents, as well as emerging amyloid-depleting agents designed to remove existing deposits, emphasizing that these strategies remain under clinical evaluation. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
